Full video transcriptClick to expand
Auto-generated transcript of @kelseymounjaroandme's video. Quoted here for educational fact-check commentary; original creator retains all rights to the video content.
- 0:00The day, the music died and they were singing
- 0:09Bye, by Miss American Pie
- 0:14Drove my Chevy to the levy, but the levy was dry
- 0:20Them good old boys were drinking whiskey and rye
- 0:25Singing this will be the day that I die
- 0:30This will be the day that I die
Tirzepatide weight loss and body confidence: what TikTok gets right and wrong
Quick answer
This video contains no spoken medical claims; it is a lifestyle post set to the lyrics of 'American Pie' by Don McLean within a tirzepatide weight loss documentation series. The creator's username and hashtags suggest ongoing use of Mounjaro (tirzepatide), a dual GIP/GLP-1 receptor agonist with FDA approval for type 2 diabetes and, as Zepbound, for chronic weight management. No clinical statements were made that require verification or correction.
Video review standard
Clinical fact-check snapshot
FormBlends treats social health videos as a starting point, then checks the claim against medical context, source quality, safety limits, and whether licensed provider review belongs in the next step.
Evidence signal
Source-backed review
Regulatory reality
Compounded Tirzepatide access requires the right clinical path
Safety screen
Viral claims can miss contraindications, dose escalation, medication interactions, and quality-control risks.
This page currently connects to 7 source-backed evidence items through visible references or structured citation data.
PubMed evidence trail
Research sources used to frame this page
For Tirzepatide weight loss and body confidence: what TikTok gets right and wrong, FormBlends checks the page topic against primary trials, systematic reviews, guidelines, and current PubMed-indexed literature where available. These citations are context, not medical advice, proof of eligibility, or a claim that every study applies to every patient.
Tirzepatide Once Weekly for the Treatment of Obesity
Primary SURMOUNT-1 trial source for tirzepatide weight-loss ranges and tolerability.
PubMed
Continued Treatment With Tirzepatide for Maintenance of Weight Reduction
Used for continuation, stopping, and maintenance questions after initial weight loss.
PubMed
Efficacy of GLP-1 Receptor Agonists on Weight Loss, BMI, and Waist Circumference
A broad meta-analysis anchor for GLP-1 weight-loss effect and class-level comparisons.
PubMed
Discontinuing glucagon-like peptide-1 receptor agonists and body habitus
Used for pages discussing stopping therapy, weight regain, and long-term planning.
PubMed
Provider decision path
Use local research to choose a safer review path
Direct answer
Compounded Tirzepatide is best used to compare access, oversight, pricing, pharmacy quality, and patient support before starting care.
Evidence check
Directory pages should connect local intent with provider standards, pharmacy transparency, and practical next steps.
Safety check
Provider quality, pharmacy source, prescribing model, and follow-up support can matter as much as the medication name.
Next step
When you are ready, the get-started flow can collect the details needed for a prescription review instead of leaving you to guess.
Claim path
Keep researching this tirzepatide video claims cluster
Best for searchers deciding whether tirzepatide claims are stronger, safer, or more relevant than semaglutide claims.
Page-specific review note
What this exact clip is really saying
This FormBlends review is specific to "Tirzepatide weight loss and body confidence: what TikTok gets right and wrong" from KELSEY 🦋 💉. We read the clip as a GLP-1 social video fact-checks claim about Compounded Tirzepatide, then separate the useful signal from what a short social video cannot prove. The page-specific claim focus is: This video contains no spoken medical claims; it is a lifestyle post set to the lyrics of 'American Pie' by Don McLean within a tirzepatide weight loss documentation series.
The reason this review is not generic is the source wording and the canonical claim label "glp1 roll on 2026 to finding my style and feeling confident again." In this clip, the useful excerpt is: "The day, the music died and they were singing Bye, by Miss American Pie Drove my Chevy to the levy, but the levy was dry Them good old boys were drinking whiskey and rye Singing this will be the day that I die This will be the day that I..." That wording changes the review because it points to Compounded Tirzepatide safety, access, evidence, and fit, not a one-size-fits-all protocol.
The source trail for this page is checked against Tirzepatide Once Weekly for the Treatment of Obesity (2022), Continued Treatment With Tirzepatide for Maintenance of Weight Reduction (2024), and Tirzepatide for Obesity Treatment and Diabetes Prevention (2025), plus the creator's own wording. Compounded Tirzepatide still needs an eligibility review, medication-interaction screen, access check, and quality-control review before anyone treats a social clip as medical advice.
Claim verdict
The useful answer behind this video
This page is built to answer the specific claim behind the clip, then separate what is useful from what still needs clinical context. That makes the URL more than a repost: it gives Google, readers, and AI retrieval systems a concise verdict with source and safety boundaries.
Claim being checked
This video contains no spoken medical claims; it is a lifestyle post set to the lyrics of 'American Pie' by Don McLean within a tirzepatide weight loss documentation series.
FormBlends verdict
Compounded Tirzepatide safety, access, evidence, and fit
Evidence strength
Source-backed review with clinical or regulatory citations.
Patient-safe next step
Compare the claim with the Compounded Tirzepatide guide, safety notes, access rules, and a licensed-provider review.
What to do with this video
Use the clip as a claim to verify, not a treatment plan
What it helps with
- This video contains no spoken medical claims; it is a lifestyle post set to the lyrics of 'American Pie' by Don McLean within a tirzepatide weight loss documentation series. The creator's username and hashtags suggest ongoing use of Mounjaro (tirzepatide), a dual GIP/GLP-1 receptor agonist with FDA approval for type 2 diabetes and, as Zepbound, for chronic weight management. No clinical statements were made that require verification or correction.
- This video contains zero spoken health claims; the transcript is entirely song lyrics and nothing in it requires medical fact-checking.
- Tirzepatide (Mounjaro/Zepbound) showed a mean 20.9% body weight reduction at 15mg in SURMOUNT-1 (Jastreboff et al., 2022, NEJM), but individual outcomes vary significantly.
What it may miss
- It may not cover eligibility, contraindications, medication interactions, lab history, or dose escalation.
- Compounded Tirzepatide decisions still need source quality, legal access, and provider oversight checks.
- Social video captions rarely show the full evidence base behind a claim.
Best next step
Compare the claim against the Compounded Tirzepatide guide, cost path, safety notes, and provider review before acting.
Review Compounded TirzepatideWhat You'll Learn
- This video contains zero spoken health claims; the transcript is entirely song lyrics and nothing in it requires medical fact-checking.
- Tirzepatide (Mounjaro/Zepbound) showed a mean 20.9% body weight reduction at 15mg in SURMOUNT-1 (Jastreboff et al., 2022, NEJM), but individual outcomes vary significantly.
- Mounjaro is FDA-approved for type 2 diabetes; Zepbound is the FDA-approved brand for chronic weight management. They contain the same molecule but carry different labeled indications.
- Compounded tirzepatide is not FDA-approved and has not been evaluated for safety or efficacy equivalence to brand-name products, per FDA guidance updated in 2024.
- Social media weight loss documentation, even from credible and transparent creators, reflects individual experience and should not be used as a benchmark for expected personal outcomes.
- Quality-of-life improvements including self-reported wellbeing are documented in tirzepatide clinical data (Wilding et al., 2023, Diabetes Obesity and Metabolism), giving some clinical grounding to confidence-related narratives.
- GLP-1 and GIP receptor agonists are prescription-only medications; no TikTok video, regardless of how relatable, substitutes for a clinician evaluation.
Our take · Written by FormBlends editorial team · Reviewed by FormBlends Medical Team · This is not a transcript. It is our independent review of the video above.
What did @kelseymounjaroandme actually say?
Nothing about weight loss, GLP-1 medications, or health at all. The entire spoken content of this video is a rendition of Don McLean's 1971 classic "American Pie," including lyrics like "drove my Chevy to the levy, but the levy was dry" and "this will be the day that I die." There are no medical claims made in the transcript whatsoever.
The video's context clues, its hashtags (#weightlosstransformation, #trend) and the creator's username @kelseymounjaroandme, tell us this is part of a GLP-1 weight loss journey series. The caption references "finding my style and feeling confident again" with a target of 2026. But the actual spoken content? Pure Don McLean. No dosing advice, no before-and-after claims, no statements about tirzepatide efficacy. Just a levy that was dry.
This matters because fact-checking requires something to check. A song is not a health claim. The video appears to be a mood or lifestyle post within a broader weight loss documentation series, not an informational video about GLP-1 medications.
Does the science back this up?
There is no scientific claim in this video to evaluate. That said, since the creator documents a Mounjaro (tirzepatide) journey, it is worth noting what the evidence actually says about the drug referenced in their username.
Tirzepatide, the active ingredient in Mounjaro and Zepbound, is a dual GIP and GLP-1 receptor agonist. The SURMOUNT-1 trial (Jastreboff et al., 2022, New England Journal of Medicine) found that participants taking the highest dose (15 mg weekly) lost a mean of 20.9% of body weight over 72 weeks compared to 3.1% with placebo. That is a meaningful result, and it is why this drug has generated so much public interest and social media content.
The confidence and style-related themes in the caption are consistent with documented quality-of-life improvements reported by GLP-1 users. A 2023 study by Wilding et al. in Diabetes, Obesity and Metabolism found significant improvements in patient-reported outcomes including physical function and self-reported wellbeing among tirzepatide users. The emotional arc this creator seems to be documenting has real clinical data behind it, even if none of that data is presented in this particular video.
What did they get wrong (or right)?
They got nothing wrong medically because they said nothing medical. Credit where it is due: not every post in a health journey series needs to be a clinical explainer. This video makes no dangerous claims, promotes no dubious stacks, and does not misrepresent any drug's mechanism or efficacy.
The absence of misinformation is actually notable in a TikTok space that frequently features creators overstating GLP-1 results, recommending specific doses to followers, or implying that compounded semaglutide is equivalent to brand-name Wegovy. This video does none of those things.
If there is a minor concern, it is contextual rather than factual. The username itself, @kelseymounjaroandme, implicitly associates the creator's transformation with Mounjaro. Viewers scrolling through may attribute visible physical changes entirely to the medication without understanding that clinical outcomes vary significantly based on adherence, diet, activity, and individual metabolic response. But that is a platform-level concern about parasocial health influence, not a factual error in this specific video.
What should you actually know?
If you landed on this fact-check because you are curious about Mounjaro or tirzepatide for weight management, here is what the evidence actually supports.
- Tirzepatide is FDA-approved under the brand name Zepbound specifically for chronic weight management in adults with obesity or overweight with at least one weight-related condition. Mounjaro is approved for type 2 diabetes. These are different approvals with different labeled indications.
- The SURMOUNT program trials are the most robust evidence base for tirzepatide in weight management. Results at the highest doses are clinically significant, but average results in trials are not individual predictions. Some people lose substantially more, some substantially less.
- Weight loss documented on social media by creators like this one reflects individual experience, not average outcomes. The Jastreboff et al. 2022 NEJM trial reported a wide range of individual responses even within the same dose group.
- Compounded tirzepatide is not the same as brand-name Mounjaro or Zepbound. The FDA has consistently stated that compounded drugs are not FDA-approved and have not been evaluated for safety, efficacy, or quality. Do not let social media content, however well-intentioned, blur that line.
- GLP-1 and GIP receptor agonists are prescription medications. Any decision about whether they are appropriate for you requires a licensed clinician who knows your full medical history.
Bottom line
This video is a vibe, not a health tutorial. The creator sang a song. Nothing here requires correction. But the broader category of GLP-1 content on TikTok carries real informational stakes, and viewers should approach even sympathetic, relatable creators with the same critical lens they would apply to any health information source.
Interested in GLP-1 or peptide therapy?
Get matched with licensed-provider review to help decide if it is right for you.
About the Creator
KELSEY 🦋 💉 · TikTok creator
342.0K views on this video
Roll on 2026 to finding my style and feeling confident again. ✨🫶🏼 #weightlosstransformation #trend
Frequently asked questions
Quick answers based on this video and our medical team review.
What does the video say about this video contains zero spoken health claims; the transcript?
This video contains zero spoken health claims; the transcript is entirely song lyrics and nothing in it requires medical fact-checking.
What does the video say about tirzepatide (mounjaro/zepbound) showed a mean 20.9% body weight reduction at?
Tirzepatide (Mounjaro/Zepbound) showed a mean 20.9% body weight reduction at 15mg in SURMOUNT-1 (Jastreboff et al., 2022, NEJM), but individual outcomes vary significantly.
What does the video say about mounjaro?
Mounjaro is FDA-approved for type 2 diabetes; Zepbound is the FDA-approved brand for chronic weight management. They contain the same molecule but carry different labeled indications.
What does the video say about compounded tirzepatide?
Compounded tirzepatide is not FDA-approved and has not been evaluated for safety or efficacy equivalence to brand-name products, per FDA guidance updated in 2024.
What does the video say about social media weight loss documentation, even from credible?
Social media weight loss documentation, even from credible and transparent creators, reflects individual experience and should not be used as a benchmark for expected personal outcomes.
What does the video say about quality-of-life improvements including self-reported wellbeing?
Quality-of-life improvements including self-reported wellbeing are documented in tirzepatide clinical data (Wilding et al., 2023, Diabetes Obesity and Metabolism), giving some clinical grounding to confidence-related narratives.
Sources & references
Citations extracted from our medical team's review. Click any citation to search PubMed.
Read More on This Topic
Our written guides go deeper with dosing details, comparison tables, and medical-team reviewed protocols.
Not medical advice. This video was made by KELSEY 🦋 💉, not by FormBlends. Our write-up above is an editorial review, not a medical recommendation. Talk to your doctor before making any decisions about medications or treatments.